Key facts
- Notable investors include Leader Venture Capital, Tsingzhi Capital, Shanghai TusPark, CR Life Sciences, Hatchip Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Yiwei Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Yiwei Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yiwei Biotech
Developer of bio and pharmaceutical technology products based in Suzhou, Jiangsu. The company's main business covers technology development, technical consultation, technical service, and technology transfer in the fields of biology and medical technology (except human stem cells, gene diagnosis and treatment technology development and application) and medical device management.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2019
- Employees
- 4
- Website
- carrierbiomed.com/
- Ownership
- Privately Held (backing)
Yiwei Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yiwei Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yiwei Biotech in its N-PORT filings yet. We sweep new filings monthly.